

LIST OF TABLES

Table	Title	Page No.
2.1	INFLATED HUMAN LUNG MORPHOLOGY-DIMENSIONS	17
2.2	CRITICAL ISSUES IN LUNG DELIVERY	22
3.1	ESTIMATION OF BLOOD GLUCOSE LEVEL IN SERUM BY GOD/POD METHOD	92
3.2	ESTIMATION OF INSULIN BY BCA METHOD	93
3.3	ESTIMATION OF PEAK AREA OF ISULIN BY HPLC METHOD	94
3.4	ESTIMATION OF BLOOD CALCIUM LEVEL IN SERUM BY ORTHO-CRESOLPHTHALEIN COMPLEXONE METHOD	95
3.5	ESTIMATION OF CALCITONIN BY BCA METHOD	96
3.6	ESTIMATION OF PEAK AREA OF CALCITONIN BY HPLC METHOD	97
4.1	COMPOSITION OF INSULIN FORMULATIONS FOR INTRATRACHEAL ADMINISTRATION	123-24
4.2	STATISTICAL DATA ANALYSIS	125
4.3	PHARMACODYNAMIC PARAMETERS AFTER SUBCUTANEOUS ADMINISTRATION OF INSULIN IN RATS	126
4.4	PHARMACODYNAMIC PARAMETERS AFTER INTRATRACHEAL ADMINISTRATION OF DIFFERENT FORMULATIONS OF INSULIN	127
4.5	PHARMACODYNAMIC PARAMETERS AFTER SUBCUTANEOUS ADMINISTRATION OF CALCITONIN IN RATS	128
4.6	STATISTICAL DATA ANALYSIS	129
4.7	PHARMACODYNAMICS OF CALCITONIN FORMULATIONS WITH DIFFERENT pH ADMINISTERED INTRATRACHEALLY IN RATS	130

Table	Title	Page No.
4.8	COMPOSITION AND PHARMACODYNAMICS OF THE CALCITONIN FORMULATIONS WITH PENETRATION ENHANCERS FOR INYTRATRACHEAL ADMINISTRATION	131
4.9	COMPOSITION AND PHARMACODYNAMICS OF THE CALCITONIN FORMULATIONS WITH PROTEASE INHIBITORS FOR INYTRATRACHEAL ADMINISTRATION	132
4.10	COMPOSITION AND PHARMACODYNAMICS OF THE CALCITONIN FORMULATIONS WITH COMBINATION OF PENETRATION ENHANCERS AND PROTEASE INHIBITORS FOR INYTRATRACHEAL ADMINISYTRATION	133
5.1	COMPOSITION OF INSULIN FORMULATIONS FOR <i>IN VITRO</i> STUDY	156
5.2	COMPOSITION OF CALCITONIN FORMULATIONS FOR <i>IN VITRO</i> STUDY	157
5.3	BLOOD GLUCOSE REDUCTION AFTER INTRATRACHEAL ADMINISTRATION OF INSULIN IN RATS	158
5.4	BLOOD CALCIUM REDUCTION AFTER INTRATRACHEAL ADMINISTRATION OF CALCITONIN IN RATS	159
5.5	<i>IN VITRO-IN VIVO</i> CORRELATION OF INSULIN AND CALCITONIN FORMULATIONS	160
6.1	COMPOSITION OF INSULIN FORMULATIONS	190
6.2	PARTICLE SIZE DISTRIBUTION OF INSULIN AND LACTOSE	191
6.3	DEPOSITION OF INSULIN AND LACTOSE FROM DIFFERENT FORMULATIONS AT A FLOW RATE OF 30 l/min.	192

Table	Title	Page No.
6.4	DEPOSITION OF INSULIN AND LACTOSE FROM DIFFERENT FORMULATIONS AT A FLOW RATE OF 60.0 l/min	193
6.5	FLOW PROPERTIES OF INSULIN WITH CARRIER	194
6.6	COMPOSITION OF CALCITONIN FORMULATIONS	195
6.7	PARTICLE SIZE DISTRIBUTION OF CALCITONIN POWDER MIXTURE AND LACTOSE	196
6.8	FLOW PROPERTIES OF CALCITONIN WITH CARRIER	197
6.9	COMPARISON OF INSULIN AND CALCITONIN DPI	198